Key Points {#FPar1}
==========

Our study found a high prevalence of potentially harmful medication (PHM) exposure among community-dwelling older adults.The proportion of participants with at least one PHM use was 58.7% for Anticholinergic Cognitive Burden, 36.6% for Drug Burden Index-sedative properties, 24.1% for Drug Burden Index-anticholinergic properties, and 19.2% for the American Geriatrics Society Beers criteria.Among the above criteria, Drug Burden Index significantly predicted a decline in quality of life among community-dwelling older adults after adjusting for other covariates.

Introduction {#Sec1}
============

Despite an increasing awareness of potentially harmful medications (PHMs), their usage has become widespread, along with a growing chronic disease epidemic among aging populations \[[@CR1]\]. Studies conducted in outpatient settings in several countries consistently report a PHM prevalence of 30% or higher, using different PHM criteria \[[@CR2]--[@CR5]\]. There is some evidence that PHM burden, especially the anticholinergic \[[@CR6]\] and sedative effects \[[@CR7]\], is associated with adverse drug events, decline in physical function, and excessive healthcare utilization \[[@CR8]--[@CR10]\]. Based on an estimation, medication-related problems are found to cost the US more than \$170 billion every year \[[@CR9]\].

PHMs are defined in several drug lists, such as the American Geriatrics Society Beers criteria \[[@CR11]\] and the STOPP/START criteria \[[@CR12]\]. In addition to these criteria, several scales have been proposed to quantify the burden of medications on older adults, especially with a focus on anticholinergic effects and sedative effects. One of the widely used scales is the Drug Burden Index (DBI) \[[@CR13]\], which was developed as a measure of overall exposure to medications with anticholinergic (DBI-Ach) and sedative (DBI-Se) properties; the scale implements the principle of dose response to quantify the medication burden. Previous studies have shown associations between higher DBI scores and lower physical function \[[@CR13]--[@CR16]\], lower cognitive function \[[@CR16]\], increased hospital admissions \[[@CR17]\], and a higher fall rate \[[@CR18]\].

The Anticholinergic Cognitive Burden (ACB) \[[@CR19]\] is another widely accepted PHM scale that uses ordinal scores to rank medications according to their clinically relevant cognitive effects. Based on a community-based observational study, every 1-point increase in the ACB score was associated with a decline in the Mini-Mental State Examination (MMSE) of 0.33 points over 2 years and a 26% increase in the risk of death \[[@CR20]\]. ACB scores have also been shown to predict functional impairment and low cognitive performance \[[@CR21], [@CR22]\]. In addition to the DBI and ACB, polypharmacy (i.e. the concomitant use of more than a certain number of drugs) is a simple, albeit potentially effective, predictor of PHM use \[[@CR23]--[@CR27]\]. Furthermore, polypharmacy itself has been shown to predict excess deaths \[[@CR28]\], increased fall risk \[[@CR29]\], and increased readmission rates \[[@CR30]\].

As stated above, PHM scales have been shown to predict healthcare outcomes such as functional decline \[[@CR13]--[@CR16]\], hospital admission \[[@CR17]\], and mortality \[[@CR20], [@CR28]\]; however, the effect of PHMs on quality of life (QoL) has not been well-studied. This is surprising considering that PHMs may lead to adverse drug events that affect patients' morbidity, which in turn greatly influences QoL, and that QoL is a fundamental aspect of patient-centered care. Bosboom et al. found that DBI scores \> 0 and the number of medications \> 5 both predicted a decline in QoL among nursing facility residents with a diagnosis of dementia \[[@CR31]\]. On the contrary, Franic and Jiang reported that the use of Beers list PHMs was not a significant predictor of QoL among community-dwelling older adults \[[@CR32]\]. To our knowledge, no study has examined the association between quantified PHM scores and change in QoL among community-dwelling older adults. Given the prevalence of PHM use among older adults, it is vital to understand its impact on QoL within a community context.

The objectives of this study were to investigate associations between PHM use and change in health-related QoL among community-dwelling older adults and to compare the predictive capacity of several PHM scales.

Methods {#Sec2}
=======

Study Design and Setting {#Sec3}
------------------------

We conducted a retrospective cohort study using data collected for Falls Free PA, an interventional study comparing falls incidence between participants of Pennsylvania's Healthy Steps for Older Adults (HSOA) program and a control group of older adults who did not participate in HSOA but visited the same senior centers. For our current study, the Falls Free PA data were linked to individual-level prescription claims data from Pennsylvania's Pharmaceutical Assistance Contract for the Elderly (PACE) program. The original Falls Free PA was conducted from 2010 to 2013 and the University of Pittsburgh Institutional Review Board approved the protocol. The protocol details and results have been published elsewhere \[[@CR33]\].

Study Sample {#Sec4}
------------

Falls Free PA included a total of 1829 patients aged 50 years or older who visited senior centers and participated in Pennsylvania Department of Aging programs. Potential participants who were unable to provide informed consent, spoke languages other than English or Spanish, and were unable to participate in telephone follow-up calls were excluded \[[@CR33]\]. Among the Falls Free PA participants, those who also participated and utilized Pennsylvania's PACE program between September 2010 and March 2012 were included in our analysis. Eligibility criteria for Pennsylvania's PACE program were (1) adults aged 65 years or older; (2) Pennsylvania residency for at least 90 days; (3) not being enrolled in the Department of Human Service's Medicaid prescription benefit, (4) and a total income of \$14,500 or less (for a married couple, combined total income must be \$17,700 or less) \[[@CR34]\]. As of January 2015, 106,548 older adults were enrolled in the PACE program in Pennsylvania \[[@CR35]\].

Outcome Measurements {#Sec5}
--------------------

The primary outcome measurement of interest was the EuroQoL five dimensions three-level version (EQ-5D-3L) summary index \[[@CR36]\] at baseline and 6- and 12-month follow-up. The EQ-5D-3L is a standardized measurement for generic health-related QoL that has five subdomain scores consisting of mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each of the five domains assesses one of three responses based on levels of severity (no problems/some or moderate problems/extreme problems). EQ-5D-3L health state responses can be summarized into a single summary index based on response profiles, ranging from 0 (death) to 1 (complete health), by applying weighted scores for each dimension. The EQ-5D-3L has been validated in diverse patient populations in multiple settings \[[@CR37]\].

Exposure Variables: Potentially Harmful Medication Use {#Sec6}
------------------------------------------------------

The following five PHM scales were calculated based on the PACE prescription claims data between baseline and the 12-month follow-up: cumulative ACB, cumulative DBI-Se, cumulative DBI-ACh, number of regular medications, and number of PHMs listed on the 2015 American Geriatrics Society 2015 updated Beers criteria \[[@CR11]\]. For the PHM scale calculation, we included all forms of oral, suppository, and transdermal medications.

First, we calculated the three cumulative indices (ACB, DBI-Se, and DBI-ACh), which utilize duration of drug exposure. The duration of exposure to each individual prescription drug were summed during the study period and then divided by days between baseline and the 12-month follow-up, adapting an equation previously described by Salahudeen et al. \[[@CR38]\]. The cumulative ACB was calculated based on the following equation:$$\documentclass[12pt]{minimal}
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In addition to the time of exposure, the cumulative DBI-Se and DBI-ACh also considers cumulative drug dose. Based on the original DBI equation described by Hilmer et al. \[[@CR13]\] and a modified version by Salahudeen et al. \[[@CR38]\], we calculated the DBI-Se and DBI-ACh using the following equations. Medications that were prescribed on a short-term, as needed basis were excluded from the DBI calculation:$$\documentclass[12pt]{minimal}
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All the cumulative indices (ACB, DBI-Se, and DBI-ACh) used in this study were calculated based on the above equations.

Second, we identified the number of distinct regular medications and regular PHMs listed on the Beers list. For the purposes of the current study, we considered prescription drugs for which claims were provided for at least 30 days and at least twice during the study period to be regular drugs. Study participants were also asked to report the number of regular drugs at the 6-month follow-up for verification purposes. For our measurement, we adopted the list of drugs that were recommended to be avoided in older adults as per Table 2 of the American Geriatrics Society 2015 updated Beers criteria \[[@CR11]\] (ESM 4). Due to data limitations, we did not include drugs, with exceptions, that require laboratory results or prescription indications (e.g. doxazosin; avoid use as an antihypertensive).

Other Study Measures {#Sec7}
--------------------

We collected baseline patient characteristics, including age, sex, ethnicity/race, marital status, living situation, education, income level, use of assistive devices for walking, recent history of falls, and self-reported comorbidity data. We also calculated the baseline number of comorbidities based on dichotomized responses with regard to the following 17 conditions: stroke, diabetes mellitus, hypertension, heart attack, macular degeneration, arthritis, osteoporosis, glaucoma, inner ear problem, depression, chronic obstructive pulmonary disorder or asthma, congestive heart failure, peripheral neuropathy, Parkinson's disease, cognitive impairment, any fracture after 50 years of age, and a current or previous history of cancer. In addition, participants' baseline memory impairment test scores were recorded as a covariate.

Statistical Analyses {#Sec8}
--------------------

We hypothesized that higher scores in all four PHM scales would be associated with lower EQ-5D index scores, after adjusting for the baseline covariates. Descriptive statistics and simple linear regression for each explanatory variable were performed to assess data properties and potential associations between each explanatory variable and the EQ-5D index. Considering a longitudinal data structure for the EQ-5D index, generalized mixed-effects models were used to investigate EQ-5D index change over time using subject ID as level 2 and measurement time point as level 1. The missing data pattern was analyzed to examine assumptions for mixed effect models. As indicators for model selection, Snijders/Bosker R-squared statistics and the intraclass correlation coefficient (ICC) were used. The residuals of the fitted models were calculated and assessed graphically using histogram and Q--Q plots. Multicollinearity was tested based on the variance inflation factor, with a cut-off at 10. We used a significance level of 0.05 for hypothesis testing. All statistical analyses were performed using STATA/SE 14.2 (StataCorp LLC, College Station, TX, USA).

Results {#Sec9}
=======

A total of 426 community-dwelling adults aged 65 years or older who participated in Falls Free PA at senior centers and had also received at least one prescription through Pennsylvania's PACE program were included in the analysis. Table [1](#Tab1){ref-type="table"} reveals the participants' baseline demographics and the EQ-5D-3L summary index over time. Of the 17 index conditions, the mean number of comorbidities among study participants was 3.9 (standard deviation \[SD\] 1.9). The mean EQ-5D-3L summary index at baseline and 6- and 12-month follow-up were 0.82 (SD 0.14), 0.82 (SD 0.15), and 0.83 (SD 0.15), respectively.Table 1Baseline characteristics of study participantsPACE participants \[*N* = 426\]Age, years \[mean (SD)\]78.57 (6.72)Male sex48 (11.27)Hispanic/Latin5 (1.17)Race^a^ American Indian/Alaskan Native1 (0.23) Asian1 (0.23) Black33 (7.75) White388 (91.08) Other2 (0.47)Marital status^b^ Single44 (10.33) Married44 (10.33) Separated2 (0.47) Widowed302 (70.89) Divorced32 (7.51) Live with someone108 (25.35)Education Never attended school-- Grade 1--818 (4.23) Grade 9--1168 (15.96) Grade 12 or GED244 (57.28) College 1--374 (17.37) College 4 or more22 (5.16)Income---sufficient for daily living^c^293 (68.78)Living in an urban area279 (65.49)Fall in the last year135 (31.69)Fall in the past 30 days34 (7.98)Use of assistive devices136 (31.92)Self-rated mobility \[mean (SD)\]^d^2.77 (1.03)Self-rated balance \[mean (SD)\]^d^3.01 (0.96)Number of comorbidities (per total)3.85 (1.90)Memory score (range 0--8, 8:completely recalled four items)6.18 (1.63)EQ-5D, baseline \[mean (SD)\]0.82 (0.14)EQ-5D, 6-month follow-up \[mean (SD)\]0.82 (0.15)EQ-5D, 12-month follow-up \[mean (SD)\]0.83 (0.15)Data are expressed as *n* (%) unless otherwise specified*PACE* Pharmaceutical Assistance Contract for the Elderly, *GED* General Education Development Certificate, *EQ*-*5D* EuroQoL five-dimension questionnaire, *SD* standard deviation^a^ *n* = 425^b^ *n* = 424^c^ *n* = 368^d^ Scores were assessed using 5-point Likert scales ranging from 1 (excellent) to 5 (poor)

The mean and distribution of prescription-related variables are summarized in Table [2](#Tab2){ref-type="table"}. The proportion of participants with at least one PHM use was 58.7% for ACB, 36.6% for DBI-Se, 24.1% for DBI-Ach, and 19.2% for the Beers list. The most common PHMs based on each scale are listed in ESM 5--8. The number of regular medications based on the claims data was 4.1 (SD 3.0, range 0--14), which was concordant with the number of self-reported medications at 6 months' follow-up (see Table [2](#Tab2){ref-type="table"}). Table [3](#Tab3){ref-type="table"} shows the correlation coefficient between the score of each pair of PHM scales, which ranged from 0.17 (DBI-Se and DBI-Ach) to 0.57 (ACB and DBI-ACh).Table 2Potentially harmful medication-related variablesPHM variablesMeanSDMinimumMaximumACB 0--12 months0.550.8704.5DBI-Se 0--12 months0.120.2401.51DBI-Ach 0--12 months0.050.1400.94Number of prescription medications (self-report at 6-month follow-up)3.893.13015Number of prescription medications (claims data)^a^4.132.99014Number of PHMs listed on Beers criteria (claims data)^a^0.240.5303*PHM* potentially harmful medication, *ACB* Anticholinergic Cognitive Burden, *DBI*-*Se* Drug Burden Index-sedative property, *DBI*-*Ach* Drug Burden Index-anticholinergic property^a^ Number of prescription drugs for which claims were provided for at least 30 days and at least twice during the study period Table 3Correlation matrix between PHM scale scoresACBDBI-SeDBI-AChNumber of regular medications^a^Number of Beers list medications^a^ACB1.00--------DBI-Se0.421.00------DBI-Ach0.570.171.00----Number of regular medications^a^0.550.420.321.00--Number of Beers list medications^a^0.430.530.260.361.00*PHM* potentially harmful medication, *ACB* Anticholinergic Cognitive Burden, *DBI*-*Se* Drug Burden Index-sedative property, *DBI*-*Ach* Drug Burden Index-anticholinergic property^a^ Number of prescription drugs for which claims were provided for at least 30 days and at least twice during the study period

After adjusting for covariates, both DBI-Se (coefficients − 0.076, 95% CI − 0.131 to − 0.020) and DBI-Ach (coefficients − 0.095, 95% CI − 0.188 to − 0.002) significantly predicted a decline in EQ-5D index over time. In addition to the DBI-Se and DBI-Ach, low household income, number of comorbid conditions, the use of assistive devices for walking, and any history of falls in the previous year were all associated with a decline in the EQ-5D index. The ACB, number of regular medications, and number of Beers medications did not have a significant association with EQ-5D changes during the study period (Table [4](#Tab4){ref-type="table"}). Variable transformations and the use of non-parametric methods did not significantly improve the model fit, and there was no multicollinearity between independent variables included in the fitted models.Table 4Random intercept model for EQ-5D index over timeVariablesFinal model \[β (SE)\]Fixed effects Intercept0.993 (0.072)^†††^ Age− 0.001 (0.001) Sex− 0.029 (0.018) Living with someone0.001 (0.001) Income level0.033 (0.014)^††^ Number of comorbidities− 0.011 (0.003)^††^ Use of assistive devices− 0.083 (0.013)^†††^ Fall in the last year− 0.035 (0.012)^††^ DBI-Se− 0.076 (0.028)^††^ DBI-Ach− 0.095 (0.047)^†^ ACB0.006 (0.009)) Number of regular medications0.001 (0.002) Number of Beers list medications0.016 (0.013)Random effects ID_subjectsd(\_cons)0.079 (0.005) Sd (residual)0.096 (0.003) Snijders/Bosker R-squared Level 1 (measurement time point)0.218 Snijders/Bosker R-squared Level 2 (subject ID)0.316 Intraclass correlation coefficient0.405All variables included in the fitted models are reported in this table*EQ*-*5D* EuroQoL five-dimension questionnaire, *SE* standard error, *DBI*-*Se* Drug Burden Index-sedative property, *DBI*-*Ach* Drug Burden Index-anticholinergic property, *ACB* Anticholinergic Cognitive Burden^†^ *p* \< 0.05, ^††^ *p* \< 0.01, ^†††^ *p* \< 0.001

Discussion {#Sec10}
==========

Our study indicated a high prevalence of PHM exposure among relatively poor community-dwelling older adults, with variation in prevalence depending on the measure. This was concordant with previous studies that found heterogeneity to be a challenge in advancing research regarding PHMs \[[@CR31], [@CR32]\]. In our study, the predictive value of the measures for decline in QoL differed significantly, despite the moderate correlation between scores for each scale.

Head-to-head comparisons of these PHM scales, including polypharmacy, DBI, and ACB, have examined concordance and prediction capacity among the scales. Naples et al. \[[@CR39]\] found considerable differences between scales in the estimation of drug burden scores, including the ACB and the DBI. Among the scales that do not consider dose, ACB detected the highest number of medications with anticholinergic effects. Salahudeen et al. compared nine previously published PHM scales and concluded that the DBI-Ach was the strongest predictor of hospital admissions, hospitalizations for falls, and office visits \[[@CR38]\]; however, despite previous efforts to identify the best measurement, there is no consensus regarding the best PHM scale to date.

Similar to the previous literature by Salahudeen et al. \[[@CR38]\], our study indicates that DBI-Se and DBI-ACh are stronger predictors for a decline in QoL among community-dwelling older adults compared with ACB, the number of regular medications, and the number of Beers list medications. The fact that ACB, which contains drugs similar to DBI-ACh, did not reveal significant predictive capability may imply that the cumulative drug dose has an important effect on the QoL of older adults. Thus, efforts to reduce overall drug dose, as well as stopping medications, may play a key role in reducing drug-related harms and help avoid unnecessary decline in older adults' health-related QoL.

Although there has been no consensus regarding the minimum clinically important difference of EQ-5D-3L index score \[[@CR40]\], Pickard et al. found that an EQ-5D index change of 0.06 was found to be clinically meaningful \[[@CR41]\]. According to our final linear random intercept model, a 0.79-point increase in the cumulative DBI-Se or a 0.63-point increase in the cumulative DBI-ACh was associated with a 0.06 decline in EQ-5D summary index. An older adult taking a DBI-ACh medication on a daily basis at a dose twice as high as the minimum effective dose would have a cumulative DBI-ACh increase of 0.66. Based on these results, it is likely that PHMs in community-dwelling older adults may be responsible for clinically significant declines in health-related QoL.

We also found that the following patient characteristics were associated with a change in QoL over time: patient subjective perception regarding their own economic status, multimorbidity (i.e. the number of baseline chronic conditions), use of an assistive device for walking, and history of previous falls within 1 year. One strength of the current study was that we were able to adjust for these potential confounders. In addition, data gathered from the drug claims database, as well as the linked longitudinal patient cohort follow-up, enabled an accurate and valid estimation of the risk of QoL change.

Our study has several limitations. First, our model assumed complete medication adherence, while no information was available regarding participants' actual medication adherence. Based on the possibility of overestimation of drug adherence, our final model may underestimate the effect of PHM exposure on QoL. Over-the-counter medications and herbal medications were not included in the PHM scales, although current evidence suggests a rise in the use of these medications \[[@CR5]\]. In addition, a relatively small sample size might have resulted in non-significant results for ACB, the number of regular medications, and the number of Beers list medications. Furthermore, our results may not be generalizable to a population with higher morbidity due to a potential for prevalent user bias.

Conclusion {#Sec11}
==========

PHM measures incorporating dose revealed a better predictive capacity for QoL change. Reducing cumulative drug dose, as well as stopping harmful/unnecessary medications, would be important for the well-being of this population. These results can be used as the basis for further research and education, with a focus on reducing PHM use in primary care practices, if further validated in different populations.
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